My assumption is that the Brazil trials will supply the data the cd12 lacked and it just needs to fill in the gaps. Because we are in a pandemic, the approval process from those trials may be quick. The HIV BLA is fast tracked, but that does not compare to pandemic treatment approvals (or at least should)